US Stock Movement: Rapport surged on October 22 as Phase II met expectations and target price was raised

Rapport October 22 Surge Analysis

Keywords: Phase II achievement, target price increase

1. On October 20, the company announced the Phase II trial results of RAP-219 for the treatment of acute bipolar mania: 253 patients received a 3-week treatment; the trial met both primary and secondary endpoints. By week 3, the YMRS total score improved by 3.1 points over placebo (p=0.045), and the mania severity score improved by 0.4 points (p=0.024).

2. On October 21, multiple Wall Street institutions updated their Rapport ratings, with target price ranges between $50 and $91.

(Disclaimer: This content is collected and summarized by AI technology from public information and is for reference only. It does not constitute investment advice.)